Compare iShares MSCI United Kingdom (FTSE) (EWU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs GeneDx Holdings Corp — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares MSCI United Kingdom (FTSE) is the larger of the two by market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| EWU | WGS | |
|---|---|---|
Market Cap | $3.62B | $2.02B |
Volume | 923,896 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $167.51 |
52-Week Low | $41.34 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.23, up 0.65% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is testing key support at $46 amid rising UK gilt yields and inflation concerns. Recent UK housing policy announcements have boosted related sectors, but broader European economic pressures and ECB rate hikes create headwinds for the UK-focused ETF.
The outlook remains cautious given technical weakness and macroeconomic pressures from rising interest rates and energy prices. Investment opportunity exists if housing stimulus gains traction, but risks include prolonged inflation and further ECB tightening that could pressure UK equities.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
